A detailed history of Brown Advisory Inc transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Brown Advisory Inc holds 45,525 shares of FOLD stock, worth $410,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,525
Previous 45,525 -0.0%
Holding current value
$410,635
Previous $451,000 7.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$9.04 - $11.75 $4,248 - $5,522
-470 Reduced 1.02%
45,525 $451,000
Q1 2024

Apr 24, 2024

BUY
$11.43 - $14.24 $114 - $142
10 Added 0.02%
45,995 $541,000
Q3 2023

Oct 24, 2023

BUY
$11.78 - $13.86 $144,717 - $170,270
12,285 Added 36.45%
45,985 $559,000
Q4 2022

Feb 13, 2023

SELL
$9.89 - $12.7 $7,971 - $10,236
-806 Reduced 2.34%
33,700 $411,000
Q3 2022

Nov 14, 2022

BUY
$9.82 - $12.75 $7,914 - $10,276
806 Added 2.39%
34,506 $360,000
Q1 2022

May 09, 2022

SELL
$7.89 - $12.48 $31 - $49
-4 Reduced 0.01%
33,700 $319,000
Q4 2021

Jan 27, 2022

SELL
$9.82 - $12.44 $363 - $460
-37 Reduced 0.11%
33,704 $389,000
Q3 2021

Nov 12, 2021

BUY
$8.74 - $11.84 $358 - $485
41 Added 0.12%
33,741 $322,000
Q1 2021

May 14, 2021

SELL
$9.2 - $23.86 $23,055 - $59,793
-2,506 Reduced 6.92%
33,700 $333,000
Q4 2020

Feb 12, 2021

SELL
$13.47 - $24.89 $29,054 - $53,687
-2,157 Reduced 5.62%
36,206 $836,000
Q3 2020

Nov 16, 2020

SELL
$12.89 - $15.89 $6,367 - $7,849
-494 Reduced 1.27%
38,363 $542,000
Q2 2020

Aug 14, 2020

BUY
$8.86 - $15.69 $4,376 - $7,750
494 Added 1.29%
38,857 $586,000
Q4 2019

Feb 14, 2020

BUY
$7.48 - $10.75 $286,955 - $412,402
38,363 New
38,363 $374,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.53B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Brown Advisory Inc Portfolio

Follow Brown Advisory Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.